-

Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers

Software module brings AI-based cell identification and segmentation to BioTek Gen5 imaging workflows

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis.

Developed for use with compatible Agilent BioTek automated imaging systems, the module uses AI-based segmentation without requiring conventional threshold setting or parameter tuning. By incorporating the capability into the familiar Gen5 software environment, the module is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis across supported applications.

Conventional threshold-based segmentation can require researchers to establish and optimize analysis parameters for individual experiments. These additional steps can introduce user-dependent variation and present challenges as laboratories adopt higher-throughput imaging workflows and generate increasing volumes of image-based data. The Gen5 AI image analysis module provides researchers with an AI-based approach designed to simplify this process within their established BioTek imaging workflow.

The module supports label-free and fluorescence, live-cell and kinetic assays commonly used in life science and pharmaceutical research environments. Its integration with Gen5 enables researchers using compatible BioTek Cytation and Lionheart automated imagers to apply AI-based segmentation within their existing imaging assays.

“With the Gen5 AI Cell Identification Module, Agilent is bringing AI-based segmentation directly into the established BioTek imaging workflow,” Xavier Amouretti, vice president and BioTek business unit leader at Agilent, said. “This practical application of AI is designed to reduce the effort associated with image analysis and help researchers move more efficiently from image acquisition to quantitative results.”

The launch expands the image-analysis capabilities available within Gen5 and reflects Agilent’s focus on integrating automation and AI into laboratory workflows. By reducing the number of steps needed for conventional threshold setting and parameter tuning across supported applications, Gen5 AI is designed to make AI-based cell analysis more accessible, enabling researchers to focus more time on generating insights for a broad range of life science research applications, including cell biology, neuroscience, drug discovery research and related biological studies.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent to Participate in 9th Annual Evercore Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in the upcoming 9th Annual Evercore Healthcare Conference. Agilent management is scheduled to participate in a fireside chat from 10 a.m. to 10:50 a.m. EST on Tuesday, Dec. 1, 2026, in Coral Gables, Florida. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies Inc...

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow. The introduction of Su...

Agilent Completes Acquisition of Proscia

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact...
Back to Newsroom